Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.42 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.42 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.39 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.39 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | PTPN7 | P35236 | 5/20 | 0.37 |
| ▸ | HMGCR | P04035 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9823904 | 0.97 | LMNA (0.40) | LMNAEGLN1ALKBH5SUCNR1MAPK1 | |
| SCHEMBL4970367 | 0.84 | PTPN7 (0.50) | LMNASLC22A6EPHX2PTPN7HMGCR | |
| SCHEMBL4969753 | 0.82 | PTPN7 (0.57) | LMNASLC22A6EPHX2PTPN7HMGCR | |
| SCHEMBL4972765 | 0.82 | TBXAS1 (0.38) | OR51E2 | |
| SCHEMBL4972079 | 0.82 | LMNA (0.53) | LMNAEGLN1ALKBH5SUCNR1MAPK1 | |
| Heptanoate SCHEMBL29243308 | 0.82 | PTPN7 (0.67) | OR51E2SLC22A6PTPN7HMGCRTSHR | |
| SCHEMBL31520018 | 0.80 | PTPN7 (0.61) | LMNAEPHX2PTPN7HMGCRTSHR | |
| SCHEMBL31520020 | 0.80 | PTPN7 (0.61) | LMNAEPHX2PTPN7HMGCRTSHR | |
| SCHEMBL31520019 | 0.80 | PTPN7 (0.61) | LMNAEPHX2PTPN7HMGCRTSHR | |
| SCHEMBL31520021 | 0.80 | PTPN7 (0.61) | LMNAEPHX2PTPN7HMGCRTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 13273 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748840-A1 | IMIDAZO[1,2-A]PYRIDINE TYPE IRAK DEGRADATION AGENT AND USE THEREOF | TAINUORUI (TIANJIN) BIOTECHNOLOGY CO., LTD (CN) | 2026-05-27 | — | — | EP | claimed |
| EP-3365354-B1 | PEPTIDES AND PEPTIDOMIMETICS IN COMBINATION WITH T CELL ACTIVATING AND/OR CHECKPOINT INHIBITING AGENTS FOR CANCER TREATMENT | CANBAS CO LTD (JP) | 2026-02-11 | — | — | EP | claimed |
| EP-4461734-B1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC (US) | 2026-02-04 | — | — | EP | claimed |
| EP-4480953-B1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC (US) | 2026-02-04 | — | — | EP | claimed |
| EP-4606434-A2 | DEUTERATED DERIVATIVES OF RUXOLITINIB | Sun Pharmaceutical Industries, Inc. (US) | 2025-08-27 | — | — | EP | claimed |
| EP-3882249-B1 | DEUTERATED DERIVATIVES OF RUXOLITINIB | SUN PHARMACEUTICAL IND INC (US) | 2025-05-14 | — | — | EP | claimed |
| CN-119818525-A | Cytarabine amino acid ester composition and application thereof | 沈阳信达泰康医药科技有限公司 | 2025-04-15 | — | — | CN | claimed |
| CN-119745904-A | Application of paeoniflorin in preparation of medicine for treating tuberous sclerosis | 澳门大学 | 2025-04-04 | — | — | CN | claimed |
| WO-2025039774-A1 | IMIDAZO[1,2-A]PYRIDINE TYPE IRAK DEGRADATION AGENT AND USE THEREOF | 泰诺瑞(天津)生物科技有限责任公司 | 2025-02-27 | — | — | WO | claimed |
| EP-4480953-A2 | TYK2 INHIBITORS AND USES THEREOF | Alumis Inc. (US) | 2024-12-25 | — | — | EP | claimed |
| WO-2014207556-A1 | PEPTIDES AND PEPTIDOMIMETICS IN COMBINATION USES AND TREATMENTS FOR CANCER PATIENT SUBPOPULATIONS | CANBAS CO., LTD. (JP) | 2014-12-31 | — | — | WO | claimed |
| US-8796226-B2 | Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof | MAPI PHARMA LTD. (IL) | 2014-08-05 | — | — | US | claimed |
| US-20110269790-A1 | NOVEL THIENOPYRIDINES AS PHARMACOLOGICALLY ACTIVE AGENTS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGISTRATION OF SOCIETIES ACT (ACT XXI OF 1860)) (IN) | 2011-11-03 | — | — | US | claimed |
| EP-2373663-A1 | THIENOPYRIDINES AS PHARMACOLOGICALLY ACTIVE AGENTS | Council of Scientific & Industrial Research (IN) | 2011-10-12 | — | — | EP | claimed |
| WO-2010076813-A1 | THIENOPYRIDINES AS PHARMACOLOGICALLY ACTIVE AGENTS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2010-07-08 | — | — | WO | claimed |
| WO-2008112167-A1 | COMBINATION OF METFORMIN R-(+) LIPOATE AND ANTIHYPERTENSIVE AGENTS FOR THE TREATMENT OF DIABETIC HYPERGLYCEMIA AND DIABETIC COMPLICATIONS | INDIGENE PHARMACEUTICALS INC. (US) | 2008-09-18 | — | — | WO | claimed |
| US-20050220888-A1 | Controlled release compositions and methods for using same | SOUTHWEST RESEARCH INSTITUTE | 2005-10-06 | — | — | US | claimed |
| US-20050054632-A1 | Naphthyl compounds, intermediates, compositions, and methods of use | BRYANT HENRY UHLMAN (US) | 2005-03-10 | — | — | US | claimed |
| WO-2003105811-A2 | CONTROLLED RELEASE COMPOSITIONS AND METHODS FOR USING SAME | SOUTHWEST RESEARCH INSTITUTE (US) | 2003-12-24 | — | — | WO | claimed |
| US-5288716-A | Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and atherosclerosis | STEIGERWALD ARZNEIMITTELWERK GMBH (DE) | 1994-02-22 | — | — | US | claimed |